Abivax to be Added to Nasdaq Biotechnology Index

Abivax SA, a clinical-stage biotechnology company specializing in therapies for chronic inflammatory diseases, has announced its addition to the Nasdaq Biotechnology Index (NBI), effective December 22, 2025. This inclusion underscores Abivax’s significant advancements in the biotechnology sector, particularly regarding its lead candidate, obefazimod (ABX464), which is currently undergoing Phase 3 trials for treating moderately to severely active ulcerative colitis. Didier Blondel, CFO of Abivax, highlighted that this milestone not only reflects the company's progress but also boosts its visibility and credibility within the global biotechnology community.

The Nasdaq Biotechnology Index is a benchmark that tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market. Qualification for inclusion requires meeting certain criteria, including minimum market capitalization and average daily trading volume, among others. Abivax's selection for the NBI is indicative of its financial stability and growth potential within the industry.

With bases in both France and the United States, Abivax is devoted to harnessing the body's immune response to create innovative treatments. The company’s focus on developing obefazimod aligns with its mission to address chronic inflammatory conditions effectively. As it continues to progress in clinical trials, inclusion in the NBI positions Abivax as a notable player in the biotechnology landscape, potentially attracting more investors and partnerships.

For more details on the Nasdaq Biotechnology Index, you can visit their [official site](https://indexes.nasdaqomx.com/Index/Overview/NBI). Abivax is poised to leverage this prominent index listing to enhance its impact in the biotechnology market while forging ahead with its clinical developments.

The recent announcement regarding Abivax's inclusion in the Nasdaq Biotechnology Index (NBI) marks a pivotal milestone for the company and creates a compelling investment narrative moving forward. As a clinical-stage biotechnology firm specializing in innovative therapeutics for chronic inflammatory diseases, Abivax's addition to the NBI enhances its visibility and credibility in the global biotech community.

From a market perspective, including Abivax in the NBI can lead to increased investor interest, particularly from institutional funds that track the index. This visibility can stabilize share prices, potentially increase trading volume, and facilitate broader analyst coverage, which often leads to more informed investment decisions. Furthermore, the NBI's structure, which is typically seen as a gauge for biotech performance, suggests that Abivax may experience increased trading liquidity and higher valuation support as it gains access to a wider pool of investors.

Abivax's lead candidate, obefazimod, is currently in crucial Phase 3 trials for ulcerative colitis, an indication that has a significant unmet medical need. If these trials are successful, they could substantially enhance the company’s revenue potential and lead to a transformative increase in market capitalization. Investors should closely monitor trial outcomes since positive results could propel Abivax's stock price.

Overall, while the potential for growth is promising, investors should also remain cognizant of the risks associated with clinical-stage companies, including trial failures or regulatory setbacks. Diversifying investments within the biotech sector and considering risk tolerance will be essential as Abivax embarks on this new chapter. Given the prevailing market dynamics, now may be a strategic entry point for long-term investors looking to capitalize on advancements in biotech innovation.